p.76 抽出テキスト
50. Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of a contemporary population-based profile of 1536 patients in Australia. Eur Heart J 2010;31:1890–1897. https://doi.org/10.1093/eurheartj/ehq110 51. Thornhill MH, Gibson TB, Yoon F, Dayer MJ, Prendergast BD, Lockhart PB, et al. Antibiotic prophylaxis against infective endocarditis before invasive dental procedures. J Am Coll Cardiol 2022;80:1029–1041. https://doi.org/10.1016/j.jacc.2022.06.030 52. Cahill TJ, Harrison JL, Jewell P, Onakpoya I, Chambers JB, Dayer M, et al. Antibiotic prophylaxis for infective endocarditis: a systematic review and meta-analysis. Heart 2017;103:937–944. https://doi.org/10.1136/heartjnl-2015-309102 53. Glauser MP, Francioli P. Relevance of animal models to the prophylaxis of infective endocarditis. J Antimicrob Chemother 1987;20(Suppl A):87–98. https://doi.org/10. 1093/jac/20.suppl_A.87 54. Lafaurie GI, Noriega LA, Torres CC, Castillo Y, Moscoso SB, Mosquera S, et al. Impact of antibiotic prophylaxis on the incidence, nature, magnitude, and duration of bacteremia associated with dental procedures: a systematic review. J Am Dent Assoc 2019; 150:948–959.e4. https://doi.org/10.1016/j.adaj.2019.06.017 55. Overholser CD, Moreillon P, Glauser MP. Experimental bacterial endocarditis after dental extractions in rats with periodontitis. J Infect Dis 1987;155:107–112. https:// doi.org/10.1093/infdis/155.1.107 56. Veloso TR, Amiguet M, Rousson V, Giddey M, Vouillamoz J, Moreillon P, et al. Induction of experimental endocarditis by continuous low-grade bacteremia mimicking spontaneous bacteremia in humans. Infect Immun 2011;79:2006–2011. https://doi. org/10.1128/IAI.01208-10 57. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116:1736–1754. https://doi.org/ 10.1161/CIRCULATIONAHA.106.183095 58. Richey R, Wray D, Stokes T; Guideline Development Group. Prophylaxis against infective endocarditis: summary of NICE guidance. BMJ 2008;336:770–771. https:// doi.org/10.1136/bmj.39510.423148.AD 59. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. Lancet 2015;385:1219–1228. https://doi.org/10.1016/S0140-6736(14)62007-9 60. Tubiana S, Duval X, Alla F, Selton-Suty C, Tattevin P, Delahaye F, et al. The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylococcus aureus bacteremia. J Infect 2016;72:544–553. https://doi.org/10.1016/j.jinf.2016.02.003 61. Thornhill MH, Lockhart PB, Prendergast B, Chambers JB, Shanson D. NICE and antibiotic prophylaxis to prevent endocarditis. Br Dent J 2015;218:619–621. https://doi. org/10.1038/sj.bdj.2015.496 62. Tubiana S, Blotiere PO, Hoen B, Lesclous P, Millot S, Rudant J, et al. Dental procedures, antibiotic prophylaxis, and endocarditis among people with prosthetic heart valves: nationwide population based cohort and a case crossover study. BMJ 2017;358:j3776. https://doi.org/10.1136/bmj.j3776 63. Cloitre A, Duval X, Tubiana S, Giraud P, Veyrac G, Nosbaum A, et al. Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in France. Med Oral Patol Oral Cir Bucal 2019;24:e296–e304. https://doi.org/10.4317/medoral.22818 64. Gross AE, Suda KJ, Zhou J, Calip GS, Rowan SA, Hershow RC, et al. Serious antibiotic-related adverse effects following unnecessary dental prophylaxis in the United States. Infect Control Hosp Epidemiol 2021;42:110–112. https://doi.org/10. 1017/ice.2020.1261 65. Khalil D, Hultin M, Rashid MU, Lund B. Oral microflora and selection of resistance after a single dose of amoxicillin. Clin Microbiol Infect 2016;22:949.e1–949.e4. https://doi.org/ 10.1016/j.cmi.2016.08.008 66. Woodman AJ, Vidic J, Newman HN, Marsh PD. Effect of repeated high dose prophylaxis with amoxycillin on the resident oral flora of adult volunteers. J Med Microbiol 1985;19:15–23. https://doi.org/10.1099/00222615-19-1-15 67. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the prevention, diagnosis, and treatment of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for infection and cancer. Eur Heart J 2009;30:2369–2413. https://doi.org/10.1093/eurheartj/ehp285 68. Bates KE, Hall M, Shah SS, Hill KD, Pasquali SK. Trends in infective endocarditis hospitalisations at United States children’s hospitals from 2003 to 2014: impact of the 2007 American Heart Association antibiotic prophylaxis guidelines. Cardiol Young 2017;27: 686–690. https://doi.org/10.1017/S1047951116001086 69. Bikdeli B, Wang Y, Kim N, Desai MM, Quagliarello V, Krumholz HM. Trends in hospitalization rates and outcomes of endocarditis among medicare beneficiaries. J Am Coll Cardiol 2013;62:2217–2226. https://doi.org/10.1016/j.jacc.2013.07.071 70. DeSimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, et al. Temporal trends in infective endocarditis epidemiology from 2007 to 2013 in Olmsted County, MN. Am Heart J 2015;170:830–836. https://doi.org/10.1016/j.ahj.2015.07.007 71. Desimone DC, Tleyjeh IM, Correa de Sa DD, Anavekar NS, Lahr BD, Sohail MR, et al. Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association’s endocarditis prevention guidelines. Circulation 2012;126:60–64. https://doi.org/10.1161/CIRCULATIONAHA. 112.095281 72. Duval X, Delahaye F, Alla F, Tattevin P, Obadia JF, Le Moing V, et al. Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol 2012;59:1968–1976. https://doi. org/10.1016/j.jacc.2012.02.029 73. Garg P, Ko DT, Bray Jenkyn KM, Li L, Shariff SZ. Infective endocarditis hospitalizations and antibiotic prophylaxis rates before and after the 2007 American Heart Association guideline revision. Circulation 2019;140:170–180. https://doi.org/10.1161/ CIRCULATIONAHA.118.037657 74. Mackie AS, Liu W, Savu A, Marelli AJ, Kaul P. Infective endocarditis hospitalizations before and after the 2007 American Heart Association prophylaxis guidelines. Can J Cardiol 2016;32:942–948. https://doi.org/10.1016/j.cjca.2015.09.021 75. Pasquali SK, He X, Mohamad Z, McCrindle BW, Newburger JW, Li JS, et al. Trends in endocarditis hospitalizations at US children’s hospitals: impact of the 2007 American Heart Association antibiotic prophylaxis guidelines. Am Heart J 2012;163:894–899. https://doi.org/10.1016/j.ahj.2012.03.002 76. Rogers AM, Schiller NB. Impact of the first nine months of revised infective endocarditis prophylaxis guidelines at a university hospital: so far so good. J Am Soc Echocardiogr 2008;21:775. https://doi.org/10.1016/j.echo.2008.04.001 77. Thornhill MH, Dayer MJ, Forde JM, Corey GR, Chu VH, Couper DJ, et al. Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ 2011;342:d2392. https://doi.org/10. 1136/bmj.d2392 78. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol 2015;65:2070–2076. https://doi.org/10.1016/j.jacc. 2015.03.518 79. Sakai Bizmark R, Chang RR, Tsugawa Y, Zangwill KM, Kawachi I. Impact of AHA’s 2007 guideline change on incidence of infective endocarditis in infants and children. Am Heart J 2017;189:110–119. https://doi.org/10.1016/j.ahj.2017.04.006 80. Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova NN. Trends in infective endocarditis in California and New York State, 1998–2013. JAMA 2017;317: 1652–1660. https://doi.org/10.1001/jama.2017.4287 81. van den Brink FS, Swaans MJ, Hoogendijk MG, Alipour A, Kelder JC, Jaarsma W, et al. Increased incidence of infective endocarditis after the 2009 European Society of Cardiology guideline update: a nationwide study in the Netherlands. Eur Heart J Qual Care Clin Outcomes 2017;3:141–147. https://doi.org/10.1093/ehjqcco/qcw039 82. Talha KM, Baddour LM, Thornhill MH, Arshad V, Tariq W, Tleyjeh IM, et al. Escalating incidence of infective endocarditis in Europe in the 21st century. Open Heart 2021;8: e001846. https://doi.org/10.1136/openhrt-2021-001846 83. Wilson WR, Gewitz M, Lockhart PB, Bolger AF, DeSimone DC, Kazi DS, et al. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. Circulation 2021;143:e963–e978. https://doi. org/10.1161/CIR.0000000000000969 84. Havers-Borgersen E, Butt JH, Ostergaard L, Bundgaard H, Smerup M, Bruun NE, et al. Recurrent infective endocarditis versus first-time infective endocarditis after heart valve surgery. Clin Res Cardiol 2020;109:1342–1351. https://doi.org/10.1007/s00392- 020-01628-7 85. Calderon-Parra J, Kestler M, Ramos-Martinez A, Bouza E, Valerio M, de Alarcon A, et al. Clinical factors associated with reinfection versus relapse in infective endocarditis: prospective cohort study. J Clin Med 2021;10:748. https://doi.org/10.3390/ jcm10040748 86. Freitas-Ferraz AB, Tirado-Conte G, Vilacosta I, Olmos C, Saez C, Lopez J, et al. Contemporary epidemiology and outcomes in recurrent infective endocarditis. Heart 2020;106:596–602. https://doi.org/10.1136/heartjnl-2019-315433 87. Salem M, Friedrich C, Saad M, Frank D, Salem M, Puehler T, et al. Active infective native and prosthetic valve endocarditis: short- and long-term outcomes of patients after surgical treatment. J Clin Med 2021;10:1868. https://doi.org/10.3390/jcm10091868 88. Luehr M, Bauernschmitt N, Peterss S, Li Y, Heyn O, Dashkevich A, et al. Incidence and surgical outcomes of patients with native and prosthetic aortic valve endocarditis. Ann Thorac Surg 2020;110:93–101. https://doi.org/10.1016/j.athoracsur.2019.10.029 89. Anantha-Narayanan M, Reddy YNV, Sundaram V, Murad MH, Erwin PJ, Baddour LM, et al. Endocarditis risk with bioprosthetic and mechanical valves: systematic review and meta-analysis. Heart 2020;106:1413–1419. https://doi.org/10.1136/heartjnl-2020- 316718 90. Ostergaard L, Valeur N, Ihlemann N, Smerup MH, Bundgaard H, Gislason G, et al. Incidence and factors associated with infective endocarditis in patients undergoing leftsided heart valve replacement. Eur Heart J 2018;39:2668–2675. https://doi.org/10. 1093/eurheartj/ehy153 ESC Guidelines 4023 Downloaded from academic.oup.com/eurheartj/article/44/39/3948/7243107 by guest on 07 October 2026